Softwr

Healthcare · head to head

Lunit vs UpToDate

Lunit logo

Lunit

Healthcare

FDA cleared and CE marked AI for mammography, tomosynthesis and chest radiography

From
On request
Rated
-
Full reviewWebsite
UpToDate logo

UpToDate

Healthcare

Evidence-based clinical decision support for healthcare providers

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Lunit the regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.; UpToDate upToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.
  • They diverge on capability: Lunit covers Lunit INSIGHT MMG, UpToDate covers Clinical Evidence.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Lunit and UpToDate actually diverge.

Attributes where Lunit and UpToDate differ
AttributeLunitUpToDate
Pricing modelquotesubscription
PlatformsWebWeb, Mobile
FoundedUnknown1992

Identical on both: starting price (On request), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Lunit

  • Lunit INSIGHT MMG
  • Lunit INSIGHT DBT
  • Lunit INSIGHT CXR
  • Volpara density assessment
  • Volpara RiskPathways
  • Volpara dose tracking
  • PACS and mammography workstation integration

Only in UpToDate

  • Clinical Evidence
  • Drug Information
  • Calculators
  • Medical Images
  • Videos
  • CME Credits
  • EHR Systems
  • Mobile

What people use each for

The jobs each tool is most often brought in to do.

Lunit

  • A national breast screening programme evaluating AI as a second reader to reduce double reading workload where two human readers are currently mandatednot UpToDate
  • A breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on DBT specificallynot UpToDate
  • An American breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what Volpara is bought fornot UpToDate
  • A tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise filmsnot UpToDate

UpToDate

  • Patient Carenot Lunit
  • Medical Recordsnot Lunit
  • Practice Managementnot Lunit
  • Telehealthnot Lunit

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Lunit

  • The regulatory permission differs by product and by region, and INSIGHT Risk has been filed with the FDA but not cleared, so a buyer who reads a corporate press release rather than the specific clearance for their product and jurisdiction will plan a deployment they cannot legally run.
  • Detection AI changes recall rates in screening, and the downstream cost of additional diagnostic workup lands on the programme rather than on the software budget, which is the cost most screening business cases omit.
  • Performance is sensitive to the mammography vendor and acquisition protocol, so published results from a Hologic estate do not transfer to a GE or Siemens estate without local validation the buyer must fund.
  • MMG, DBT and CXR are licensed separately and Volpara modules are separate again, so a breast centre wanting detection, density and risk pathways is assembling four line items rather than buying one product.
  • Using AI as a replacement for one of two human readers is a workforce and liability decision that regulators and professional bodies treat differently in each country, so the saving that justifies the purchase may not be permitted where you operate.

UpToDate

  • UpToDate does not publish subscription prices; the vendor (Wolters Kluwer) sorts buyers into separate individual, clinic-wide, and institutional subscription tracks and requires contacting the organization through its subscription-payment-options page rather than showing a rate for any of them.

Pricing, plan by plan

Lunit

On request
  • Lunit INSIGHT$undefined/year
    • Priced per study or per annual examination volume by product
    • MMG, DBT and CXR licensed separately
    • Volpara density and RiskPathways modules quoted separately

UpToDate

On request

No published plan breakdown. See the UpToDate review.

Which should you pick?

Choose Lunit if

  • You need lunit insight mmg.
  • You also want lunit insight dbt.
Lunit review

Choose UpToDate if

  • You need clinical evidence.
  • You work on Web, Mobile.
  • You also want drug information.
UpToDate review

Questions people ask

Is Lunit or UpToDate better?
Neither clearly leads. Lunit starts at On request and UpToDate at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Lunit or UpToDate?
Lunit starts at On request and UpToDate at On request.
Does Lunit or UpToDate run on more platforms?
Lunit runs on Web. UpToDate runs on Web, Mobile.
What is Lunit best used for?
Lunit is most often used for a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated, a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically, an american breast imaging centre needing automated volumetric density assessment to meet patient density notification requirements, which is what volpara is bought for, a tuberculosis or lung screening programme in a high volume, radiologist scarce setting using chest radiography triage to prioritise films. Of those, a national breast screening programme evaluating ai as a second reader to reduce double reading workload where two human readers are currently mandated and a breast centre that moved to tomosynthesis and now has reading times it cannot staff, wanting detection support on dbt specifically are not what UpToDate is typically brought in for.
What can Lunit do that UpToDate cannot?
Lunit covers Lunit INSIGHT MMG, Lunit INSIGHT DBT, Lunit INSIGHT CXR, Volpara density assessment. UpToDate covers Clinical Evidence, Drug Information, Calculators, Medical Images.

Answered from the vendors’ own pages

Lunit: Is Lunit FDA cleared?

Yes for specific products. INSIGHT MMG, INSIGHT DBT and INSIGHT CXR Triage hold FDA 510(k) clearances. INSIGHT Risk, the five year risk prediction model, has been filed but was not cleared at the time of writing.

Lunit: Can Lunit replace a second human reader in screening?

That depends entirely on your jurisdiction and professional body guidance, not on the software. The CE mark permits clinical use; it does not authorise a workforce model.

Lunit: What did the Volpara acquisition add?

Volumetric breast density measurement, dose tracking and RiskPathways high risk programme management, which are the things American breast centres buy for density notification compliance rather than for detection.

Lunit: Is pricing published?

No. It is quoted per study or per annual volume, by product, with on premises and cloud priced differently.

Share

Related pages

More on Lunit

More on UpToDate

Keep looking

Other head to heads